Risedronate Sodium Tablet, Film Coated
Product Images NDC 65862-519

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Risedronate Sodium (NDC 65862-519). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Risedronate Fig1)

A bar chart comparing the percentage of patients by fracture site between placebo and Risedronate Sodium 5 mg. The x-axis lists fracture sites: All, Wrist, Humerus, Hip, Pelvis, Leg, and Clavicle. The y-axis shows percentage of patients, ranging from 0 to 12%. Black bars represent Risedronate Sodium 5 mg, and white bars represent placebo.*

FDA Label Image

Package Label-principal Display Panel (30 mg Blister Carton (10 x 10 Unit Dose))

Packaging label for Risedronate Sodium Tablets USP 30 mg film-coated tablets by Aurobindo Pharma Limited. The label shows a unit dose package containing 100 tablets (10 x 10 blisters). The label includes NDC 65862-518-78 and instructions for pharmacists to dispense the Medication Guide with each patient.*

FDA Label Image

Package Label-principal Display Panel (35 mg Blister Card)

Label for Risedronate Sodium Tablets USP 35 mg, film-coated tablets by Aurobindo Pharma Limited. The label indicates the dosage form and strength with a 4-week supply of tablets arranged by week. It includes instructions for use, storage directions, and manufacturer details, along with directions to take one tablet weekly on an empty stomach.*

FDA Label Image

Package Label-principal Display Panel (35 mg Blister Carton)

Packaging label for Risedronate Sodium Tablets, USP 35 mg film-coated tablets by Aurobindo Pharma USA, distributed by Aurobindo Pharma USA, Inc. The box indicates a 4 week supply (4 tablets), labeled for prescription use and once-a-week dosing. The label includes detailed instructions on how to take the tablets and storage information. The label has barcodes and specifies the product is made in India.*

FDA Label Image

Figure 2 (Risedronate Fig2)

A bar chart comparing mean percentage change in bone mineral density (BMD) with standard error for Placebo and Risedronate Sodium 5 mg groups at three anatomical sites: Lumbar Spine, Femoral Neck, and Femoral Trochanter. Sample sizes are indicated for each group and site.*

FDA Label Image

Figure 3 (Risedronate Fig3)

A bar chart comparing the mean percent change in bone mineral density (BMD) at three anatomical sites (Lumbar Spine, Femoral Neck, Femoral Trochanter) between placebo and Risedronate Sodium 5 mg groups. The chart shows data including sample sizes and standard error bars for each group.*

FDA Label Image

Figure 4 (Risedronate Fig4)

A bar chart comparing mean percent change in Bone Mineral Density (BMD) with standard error for placebo and Risedronate Sodium 5 mg groups across three body sites: Lumbar Spine, Femoral Neck, and Femoral Trochanter. Sample sizes (n) for each group are shown above each bar.*

FDA Label Image

Figure 5 (Risedronate Fig5)

Bar chart showing the incidence percentage comparing Placebo and Risedronate Sodium 5 mg groups across three categories: Patients Continuing Glucocorticoid Treatment, Patients Initiating Glucocorticoid Treatment, and Combined. Each category lists the sample size (n) for placebo and risedronate groups.*

FDA Label Image

Figure 6 (Risedronate Fig6)

A line graph comparing the percentage change over time between Risedronate Sodium 30 mg and Didronel 400 mg across Treatment, Follow-Up, and Extended Follow-Up periods up to 540 days. The x-axis represents visit days, and the y-axis shows percentage change with sample sizes noted at intervals.*

FDA Label Image

Package Label-principal Display Panel (5 mg (30 Tablet Bottle))

Packaging label for Risedronate Sodium Tablets USP 5 mg, film-coated tablets. The label indicates a 30-tablet count and is distributed by Aurobindo Pharma USA, Inc., made in India. The label includes dosing and storage instructions and a barcode.*

FDA Label Image

Package Label-principal Display Panel (5 mg Blister Carton (10 x 10 Unit-dose))

Packaging label for Risedronate Sodium Tablets, USP 5 mg film-coated tablets by Aurobindo Pharma Limited. The label shows 100 (10 x 10 blisters) Unit Dose Tablets with instructions to dispense the accompanying Medication Guide. The NDC number 65862-517-78 is visible along with dosage details and storage instructions.*

FDA Label Image

Package Label-principal Display Panel (30 mg (30 Tablet Bottle))

Label for Risedronate Sodium Tablets, USP 30 mg film-coated tablets by Aurobindo Pharma Limited. The label includes dosing details, storage instructions, distributor address in New Jersey, USA, and notes the product is made in India. Package contains 30 tablets with prominent dosage strength in a blue oval.*

FDA Label Image

Chemical Structure (Risedronate Str)

Chemical structure of Risedronate Sodium with associated 2.5 molecules of water (hydrate form). The diagram depicts the molecule's key functional groups and atomic arrangement relevant to its chemical identity.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.